AnaptysBio, Inc. (NASDAQ:ANAB) CEO Daniel Faga Sells 145,940 Shares

AnaptysBio, Inc. (NASDAQ:ANAB) CEO Daniel Faga sold 145,940 shares of the business’s stock in a transaction that occurred on Friday, March 22nd. The stock was sold at an average price of $22.78, for a total transaction of $3,324,513.20. Following the sale, the chief executive officer now directly owns 752,087 shares in the company, valued at $17,132,541.86. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Daniel Faga also recently made the following trade(s):

• On Monday, March 25th, Daniel Faga sold 3,000 shares of AnaptysBio stock. The stock was sold at an average price of $21.42, for a total transaction of $64,260.00.
• On Monday, January 8th, Daniel Faga sold 6,866 shares of AnaptysBio stock. The stock was sold at an average price of $21.81, for a total transaction of $149,747.46.

AnaptysBio Stock Down 1.0 %

Shares of NASDAQ ANAB opened at $21.38 on Thursday. The firm has a market cap of $572.13 million, a PE ratio of -3.52 and a beta of -0.28. AnaptysBio, Inc. has a 12-month low of $13.36 and a 12-month high of $27.50. The company’s fifty day simple moving average is $24.00 and its 200 day simple moving average is $20.21.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Quantbot Technologies LP bought a new position in AnaptysBio during the second quarter worth $34,000. Tower Research Capital LLC TRC boosted its stake in AnaptysBio by 248.8% during the third quarter. Tower Research Capital LLC TRC now owns 3,596 shares of the biotechnology company’s stock worth $65,000 after acquiring an additional 2,565 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in AnaptysBio by 350.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,072 shares of the biotechnology company’s stock worth $66,000 after buying an additional 2,390 shares during the last quarter. BNP Paribas Arbitrage SA raised its holdings in AnaptysBio by 75.4% during the second quarter. BNP Paribas Arbitrage SA now owns 4,984 shares of the biotechnology company’s stock worth $101,000 after buying an additional 2,142 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in AnaptysBio by 134.4% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,896 shares of the biotechnology company’s stock worth $106,000 after buying an additional 3,381 shares during the last quarter.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on ANAB shares. Piper Sandler assumed coverage on shares of AnaptysBio in a research note on Friday, February 16th. They issued an “overweight” rating and a $80.00 price objective on the stock. Stifel Nicolaus assumed coverage on shares of AnaptysBio in a research note on Wednesday, February 21st. They issued a “buy” rating and a $50.00 price objective on the stock. BTIG Research assumed coverage on shares of AnaptysBio in a research note on Monday, February 26th. They issued a “buy” rating and a $55.00 price objective on the stock. Finally, Wedbush raised shares of AnaptysBio from a “neutral” rating to an “outperform” rating and upped their price objective for the company from $20.00 to $34.00 in a research note on Tuesday, March 12th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $45.00.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.